BI
BVF Inc Portfolio holdings
AUM
$2.8B
This Quarter Return
+22.37%
1 Year Return
+17.96%
3 Year Return
+404.14%
5 Year Return
+563.41%
10 Year Return
+5,885.83%
AUM
$3.64B
AUM Growth
+$3.64B
(-9%)
Cap. Flow
-$639M
Cap. Flow
% of AUM
-17.56%
Top 10 Holdings %
Top 10 Hldgs %
62.29%
Holding
72
New
2
Increased
4
Reduced
13
Closed
10
Top Buys
| 1 |
CG Oncology
CGON
|
$82.7M |
| 2 |
Tyra Biosciences
TYRA
|
$31.5M |
| 3 |
Immunic
IMUX
|
$11.8M |
| 4 |
ALLK
Allakos
ALLK
|
$10.1M |
| 5 |
Unicycive Therapeutics
UNCY
|
$2.06M |
Top Sells
| 1 |
Axsome Therapeutics
AXSM
|
$158M |
| 2 |
Merus
MRUS
|
$71.2M |
| 3 |
CNTA
Centessa Pharmaceuticals
CNTA
|
$69.8M |
| 4 |
Janux Therapeutics
JANX
|
$62.5M |
| 5 |
Protagonist Therapeutics
PTGX
|
$57.5M |
Sector Composition
| 1 | Healthcare | 99.86% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
MoonLake Immunotherapeutics
MLTX
$3.54B
| $1.09B | 30.04% | 21,751,284 | – | – |
|
2
Kymera Therapeutics
KYMR
$2.95B
| $208M | 5.7% | 5,161,801 | – | – |
|
3
Revolution Medicines
RVMD
$7.1B
| $193M | 5.3% | 5,981,212 | – | – |
|
4
4D Molecular Therapeutics
FDMT
$288M
| $125M | 3.44% | 3,922,413 -85,000 | -2% | -$2.71M |
|
5
GH Research
GHRS
$837M
| $111M | 3.05% | 10,400,158 | – | – |
|
|
6
Janux Therapeutics
JANX
$1.37B
| $110M | 3.02% | 2,919,818 -1,660,000 | -36% | -$62.5M |
|
7
Mirum Pharmaceuticals
MIRM
$3.71B
| $110M | 3.02% | 4,370,024 | – | – |
|
|
8
Protagonist Therapeutics
PTGX
$3.67B
| $109M | 2.99% | 3,755,990 -1,988,858 | -35% | -$57.5M |
|
9
Ionis Pharmaceuticals
IONS
$6.79B
| $105M | 2.89% | 2,428,613 | – | – |
|
10
Olema Pharmaceuticals
OLMA
$375M
| $103M | 2.84% | 9,135,893 | – | – |
|
11
Kura Oncology
KURA
$686M
| $102M | 2.81% | 4,786,293 -2,586,935 | -35% | -$55.2M |
|
12
Xoma
XOMA
$392M
| $87.4M | 2.4% | 3,633,743 | – | – |
|
|
13
CG Oncology
CGON
$2.04B
| $82.7M | 2.27% | +1,884,191 | New | +$82.7M |
|
|
14
Tyra Biosciences
TYRA
$675M
| $76.4M | 2.1% | 4,661,194 +1,921,599 | +70% | +$31.5M |
|
15
ESSA Pharma
EPIX
$11.4M
| $74.3M | 2.04% | 8,748,629 | – | – |
|
16
Zymeworks
ZYME
$1.12B
| $61.8M | 1.7% | 5,870,000 | – | – |
|
17
Galapagos
GLPG
$2.07B
| $60M | 1.65% | 1,863,809 -51,300 | -3% | -$1.65M |
|
18
Cullinan Oncology
CGEM
$445M
| $54.5M | 1.5% | 3,196,701 | – | – |
|
|
19
Merus
MRUS
$4.98B
| $52.8M | 1.45% | 1,172,249 -1,580,171 | -57% | -$71.2M |
|
20
IDEAYA Biosciences
IDYA
$2.15B
| $51M | 1.4% | 1,162,306 -566,737 | -33% | -$24.9M |
|
21
Annexon
ANNX
$226M
| $50.2M | 1.38% | 7,000,000 | – | – |
|
22
Repare Therapeutics
RPTX
$71.7M
| $48.7M | 1.34% | 10,333,600 | – | – |
|
23
89bio
ETNB
$1.34B
| $47.1M | 1.3% | 4,047,354 | – | – |
|
24
Syndax Pharmaceuticals
SNDX
$1.41B
| $44.6M | 1.23% | 1,875,000 | – | – |
|
25
AC Immune
ACIU
$205M
| $43.1M | 1.19% | 14,571,236 | – | – |
|